XML 42 R29.htm IDEA: XBRL DOCUMENT
v3.24.3

INTANGIBLE ASSETS (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract] |
Summary of Finite-Lived Intangible Assets | The following table summarizes our Intangible assets, net:
|  | September 30, 2024 |  | December 31, 2023
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset – sofosbuvir |  | $ | 10,720 |  |  | $ | (7,574) |  |  | $ | — |  |  | $ | 3,146 |  |  | $ | 10,720 |  |  | $ | (7,050) |  |  | $ | — |  |  | $ | 3,670 |
Intangible asset – axicabtagene ciloleucel |  | 7,110 |  |  | (2,619) |  |  | — |  |  | 4,491 |  |  | 7,110 |  |  | (2,314) |  |  | — |  |  | 4,796 |
Intangible asset – Trodelvy |  | 11,730 |  |  | (2,813) |  |  | — |  |  | 8,917 |  |  | 11,730 |  |  | (2,002) |  |  | — |  |  | 9,728 |
Intangible asset – Hepcludex |  | 845 |  |  | (308) |  |  | — |  |  | 537 |  |  | 845 |  |  | (243) |  |  | — |  |  | 602 |
Other |  | 1,474 |  |  | (911) |  |  | 1 |  |  | 565 |  |  | 1,414 |  |  | (827) |  |  | 1 |  |  | 588 |
Total finite-lived assets |  | 31,879 |  |  | (14,224) |  |  | 1 |  |  | 17,656 |  |  | 31,819 |  |  | (12,436) |  |  | 1 |  |  | 19,384 |
Indefinite-lived assets – IPR&D(1) |  | 2,890 |  |  | — |  |  | — |  |  | 2,890 |  |  | 7,070 |  |  | — |  |  | — |  |  | 7,070 |
Total intangible assets |  | $ | 34,769 |  |  | $ | (14,224) |  |  | $ | 1 |  |  | $ | 20,546 |  |  | $ | 38,889 |  |  | $ | (12,436) |  |  | $ | 1 |  |  | $ | 26,454 |
_______________________________ (1) The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairments” below for 2024 activity. The Indefinite-lived assets – IPR&D balance as of September 30, 2024 was comprised of $1.8 billion related to SG for NSCLC and $1.1 billion related to bulevirtide.
Summary of Indefinite-Lived Intangible Assets | The following table summarizes our Intangible assets, net:
|  | September 30, 2024 |  | December 31, 2023
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset – sofosbuvir |  | $ | 10,720 |  |  | $ | (7,574) |  |  | $ | — |  |  | $ | 3,146 |  |  | $ | 10,720 |  |  | $ | (7,050) |  |  | $ | — |  |  | $ | 3,670 |
Intangible asset – axicabtagene ciloleucel |  | 7,110 |  |  | (2,619) |  |  | — |  |  | 4,491 |  |  | 7,110 |  |  | (2,314) |  |  | — |  |  | 4,796 |
Intangible asset – Trodelvy |  | 11,730 |  |  | (2,813) |  |  | — |  |  | 8,917 |  |  | 11,730 |  |  | (2,002) |  |  | — |  |  | 9,728 |
Intangible asset – Hepcludex |  | 845 |  |  | (308) |  |  | — |  |  | 537 |  |  | 845 |  |  | (243) |  |  | — |  |  | 602 |
Other |  | 1,474 |  |  | (911) |  |  | 1 |  |  | 565 |  |  | 1,414 |  |  | (827) |  |  | 1 |  |  | 588 |
Total finite-lived assets |  | 31,879 |  |  | (14,224) |  |  | 1 |  |  | 17,656 |  |  | 31,819 |  |  | (12,436) |  |  | 1 |  |  | 19,384 |
Indefinite-lived assets – IPR&D(1) |  | 2,890 |  |  | — |  |  | — |  |  | 2,890 |  |  | 7,070 |  |  | — |  |  | — |  |  | 7,070 |
Total intangible assets |  | $ | 34,769 |  |  | $ | (14,224) |  |  | $ | 1 |  |  | $ | 20,546 |  |  | $ | 38,889 |  |  | $ | (12,436) |  |  | $ | 1 |  |  | $ | 26,454 |
_______________________________ (1) The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairments” below for 2024 activity. The Indefinite-lived assets – IPR&D balance as of September 30, 2024 was comprised of $1.8 billion related to SG for NSCLC and $1.1 billion related to bulevirtide.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration